Matrix metalloproteinase -9 polymorphism and outcome after acute myocardial infarction

Abstract

ObjectivesMatrix metalloproteinases (MMPs) play an important role in the pathogenesis of coronary artery disease (CAD). This study aims to determine the association of MMP-9 genotype polymorphisms and its serum levels with the risk of acute myocardial infarction (AMI) in Egyptian patients. Also, it evaluated their role as predictors of AMI outcome after six months follow-up. MethodsSubjects included in the study were 184 patients with AMI and 180 controls. Genotyping of MMP-9-1562C>T polymorphism was carried out by PCR-based restriction digestion method. Serum MMP-9 was measured using ELIZA assay. All patients were followed for AMI complications during their hospitalization and 6 months later on. ResultsMMP-9-1562T allele was more frequent in patients than in controls (OR=1.65, 95%CI 1.09–2.15, P=0.011). the frequency of CT+TT genotypes were higher in patients with morbidity (OR=2.85, 95%CI 1.29–6.29, P=0.008) and with mortality (OR=3.21, 95%CI 1.28–8.02, P=0.012) than in those without MI complications. Serum MMP-9 levels were significantly elevated in AMI as compared to controls and more associated with TT genotype. The impairment of LV function (ΔEF, ΔLAD, ΔE/A) was more observed in the TT genotype compared with CC genotype. ConclusionsOur data suggest that MMP-9 (TT genotype) and its serum level are associated with the risk of suffering AMI in Egyptians. In addition, MMP-9 polymorphism and its level might be useful clinical biomarkers for predicting the outcome of AMI.